A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC) Meeting Abstract
| Authors: | Keane, F.; Schoenfeld, J. D.; Crowley, F.; O'Connor, C. A.; White, C.; Schwartz, C.; Brenner, R.; Larsen, M.; Park, W.; Varghese, A. M.; Yu, K. H.; Li, J.; Zervoudakis, A.; Goldberg, Z.; Chou, J. F.; Vardhana, S.; Reyngold, M.; Crane, C. H.; Tuli, R.; O'Reilly, E. M. |
| Abstract Title: | A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC) |
| Meeting Title: | 2023 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2023 Jan 19-21 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-02-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.4_suppl.725 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 725 -- Accession Number: 161485174 -- Entry Date: In Process -- Revision Date: 20230127 -- Publication Type: Article -- Supplement Title: 2/1/2023 Supplement 1 -- Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 8309333. -- Source: Cinahl |
Altmetric
Citation Impact
BMJ Impact Analytics
